Johnson & Johnson (N:JNJ)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 1 Johnson And Johnson Plz
Tel: 1-800-9505089
IR: See website
Key People
Alex Gorsky
Chairman of the Board, Chief Executive Officer
Jennifer L. Taubert
Executive Vice President - Worldwide Chairman, Pharmaceuticals
Paulus A. Stoffels
Vice Chairman- Executive Committee, Chief Scientific Officer
Joaquin Boix Duato
Vice Chairman - Executive Committee
Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Peter M. Fasolo
Chief Human Resource Officer, Executive Vice President
Michael H. Ullmann
Executive Vice President, General Counsel
Ashley McEvoy
Executive Vice President - Worldwide Chairman, Medical Devices
Thibaut Mongon
Executive Vice President, Worldwide Chairman, Consumer
Michael E. Sneed
Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Business Overview
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Financial Overview
For the three months ended 29 March 2020, Johnson & Johnson revenues increased 3% to $20.69B. Net income increased 55% to $5.8B. Revenues reflect Pharmaceutical segment increase of 9% to $11.13B, Consumer segment increase of 9% to $3.62B, United States segment increase of 6% to $10.7B, Europe segment increase of 5% to $4.83B. Net income benefited from In-process research and development decrease from $890M (expense) to $0K.
Employees: 132,200 as of Dec 29, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $389,915M as of Mar 29, 2020
Annual revenue (TTM): $82,729M as of Mar 29, 2020
EBITDA (TTM): $31,201M as of Mar 29, 2020
Net annual income (TTM): $17,166M as of Mar 29, 2020
Free cash flow (TTM): $9,738M as of Mar 29, 2020
Net Debt Last Fiscal Year: $9,559M as of Mar 29, 2020
Shares outstanding: 2,634,594,535 as of Apr 22, 2020
Index Membership: S&P 500, Dow Industry
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization